Corrected: Cardiff’s stock jumps after sharing promising PhII data for its PLK1 inhibitor in pancreatic cancer

Ayisha Sharma

News Reporter

Cardiff Oncology saw its stock rise after it announced positive Phase II data from its PLK1 inhibitor onvansertib in second-line metastatic pancreatic ductal adenocarcinoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Corrected: Cardiff’s stock jumps after sharing promising PhII data for its PLK1 inhibitor in pancreatic cancer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Cor­rect­ed: Cardiff’s stock jumps af­ter shar­ing promis­ing PhII da­ta for its PLK1 in­hibitor in pan­cre­at­ic can­cer

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Corrected: Cardiff’s stock jumps after sharing promising PhII data for its PLK1 inhibitor in pancreatic cancer